Last updated on March 2019

IMG-7289 in Patients With Myelofibrosis

Brief description of study

This is a Phase 1 open label study of an orally administered LSD1 inhibitor, IMG-7289, in patients with myelofibrosis.

This study investigates the following:

  • The safety and tolerability of IMG-7289
  • The pharmacokinetics of IMG-7289
  • The pharmacodynamic effect of IMG-7289

Clinical Study Identifier: NCT03136185

Find a site near you

Start Over

Royal Adelaide Hospital

Adelaide, Australia
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.